Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Standard Bupivacaine for Post-Rhinoplasty Analgesia
NCT07689162Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: Cumulative opioid consumption at 72 hours. Started Aug 2026; status: recruiting.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07689162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689162.